Medigus: Revoltz Commenced Prototype Manufacturing of its Micro-mobility Vehicle
September 13 2021 - 7:50AM
Medigus Ltd. (Nasdaq: MDGS), a technology company engaged in
advanced medical solutions, innovative internet technologies and
electric vehicle and charging solutions, announced today that
Revoltz, its EV joint venture (19.9% owned), has begun the
prototype manufacturing of its micro mobility vehicle.
The production has commenced in China together
with Mr. Weijian Zhou, one of Revoltz partners. Weijian Zhou is a
manufacturer of high-end scooters, E-mobility and Skiing Machines.
Mr. Zhou’s operations are equipped with advanced machining and
inspection facilities, an R&D center, and a Training
Institute.
Revoltz recently completed the preliminary
design and functional prototype of Model One, its micro-mobility
vehicle for last mile and food delivery, which is designed to
facilitate efficient delivery of smaller items in urban
environments while maintaining low and immediate transportation
costs.
A three-wheeled chassis with a wide platform
design provides maximum safety for the rider as well as complete
mobility in imperfect road conditions. The Model One design
includes two loading surfaces, front and rear, each of which can be
used flexibly with interchangeable modules, depending on the
customer’s needs. The model is designed to carry two-and-a-half
times the cargo of a traditional scooter.
The newly manufactured prototypes will be used
by Revoltz to further advance its development and to approach
potential commercial partners.
About Revoltz
Revoltz, a joint venture between Medigus,
through its wholly owned subsidiary, Charging Robotics Ltd., and
Amir Zaid and Weijian Zhou, the founders of EMuze, is a privately
held company that designs and develops electric micro-mobility
vehicles. Revoltz’s focus is developing EVs to meet the demands of
commercial users and mission-specific designs, including full work
day single charge, heavy-duty and rigid operations, Hop-on-Hop-off
modes, off-road travel and a low cost of operation.
About Medigus
Based in Israel, Medigus Ltd. (Nasdaq: MDGS) is
a technologies company that is focused on innovative growth
partnerships, mainly in advanced medical solutions, digital
commerce, and electric vehicle markets. Medigus' affiliations in
the medical solutions arena consist of ownership in ScoutCam
(OTCQB: SCTC), Inc, and Polyzion, LTD. The Company’s affiliates in
digital commerce include Gix Internet Ltd. (TASE:GIX), Jeff's
Brands and Eventer Technologies, Ltd. In the electric vehicle
market, Charging Robotics, Ltd. and Revolz are also part of the
Company’s portfolio of technology solution providers. Medigus is
traded on the Nasdaq Capital Market. To learn more about Medigus’
advanced technologies, please
visit http://www.medigus.com/investor-relations.
Cautionary Note Regarding Forward Looking
Statements
This letter may contain statements that are
“Forward-Looking Statements,” which are based upon the current
estimates, assumptions and expectations of Medigus’ management and
its knowledge of the relevant market. Medigus has tried, where
possible, to identify such information and statements by using
words such as “anticipate,” “believe,” “envision,” “estimate,”
“expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,”
“potential,” “will,” “would,” “could,” “should,” “continue,”
“contemplate” and other similar expressions and derivations thereof
in connection with any discussion of future events, trends or
prospects or future operating or financial performance, although
not all forward-looking statements contain these identifying words.
For example, Medigus is using forward looking statements when it
discusses Revoltz’s Model One design and functional prototype, the
belief that the positive initial performance assessments of the
Model One prototype reflects the innovation and engineering
incorporated in its design, and that the newly manufactured
prototypes will be used by Revoltz to further advance its
development and to approach potential commercial partners. These
forward-looking statements represent Medigus’ expectations or
beliefs concerning future events, and it is possible that the
results described in this press release will not be achieved. By
their nature, Forward-Looking Statements involve known and unknown
risks, uncertainties and other factors which may cause future
results to differ significantly from the content and implications
of such statements. Other risk factors affecting Medigus are
discussed in detail in Medigus’ filings with the Securities and
Exchange Commission. Forward-Looking Statements are pertinent only
as of the date on which they are made, and Medigus undertakes no
obligation to update or revise any Forward-Looking Statements,
whether as a result of new information, future developments or
otherwise. Neither Medigus nor its shareholders, officers and
employees, shall be liable for any action and the results of any
action taken by any person based on the information contained
herein, including without limitation the purchase or sale of
Medigus’ securities. Nothing in this letter should be deemed to be
medical or other advice of any kind.
Contact
Tali DinarChief Financial
Officer+972-8-6466-880ir@medigus.com
Medigus (NASDAQ:MDGS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Medigus (NASDAQ:MDGS)
Historical Stock Chart
From Apr 2023 to Apr 2024